Bi-Weekly UpdateSep 28, 2026 · 7 pages · Free to read

Medical Devices Bi-Weekly Industry Events & M&A Update — September 14–28, 2026

Covers 30 Medical Devices companies over September 14–28, 2026 — price moves, company news, and the one agreed transaction recorded in the window. Built for operators, acquirers and advisers who need what changed, why, and what it means.

Download PDF Download PowerPoint

-0.4%
Sector Median Move: +0.8%
S&P 500 Return: -17.9%
PROCEPT BioRobotics (PRCT): 8.3x
Precedent Deal Multiple

1 of 7

$C:\Users\dawoo\OneDrive\Desktop\Deployments\neuracap_sector_reports_fable\Code\NeuraCap_Sector_Report_Pipeline_v2.1.0\ncsr\deck_kit\assets\logo_light_full.png$

BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › MEDICAL DEVICES

Evidence and Integration Earn the Bid; Legal Overhang Takes It Back

This update covers Medical Devices over September 14–28, 2026: the period's movers, company news and the one transaction the parties agreed during the window.

September 14–28, 2026

Prepared by NeuraCap AI   ·   Confidential

Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28

Medical Devices Bi-Weekly Update   |   September 14–28, 2026   |   Confidential   |   Not investment advice

Sources & methodology

1

1 / 7 · HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › MEDICAL DEVICES

Executive summary

Over September 14–28, 2026, the medical devices group lagged the broader market: 17 of 30 covered names fell, with the median move at -0.4% against the S&P 500's +0.8%. Clinical evidence and an integration agreement drove the period's largest gains — Intuitive Surgical (ISRG) +9.8% and Senseonics (SENS) +11.3% — while litigation overhang pressured PROCEPT BioRobotics (PRCT) -17.9%. Haemonetics (HAE) was named in the period's one agreed transaction, leaving the trailing 40-deal precedent set at a median 8.3x EV/LTM EBITDA.

Key findings

17 of 30 covered names fell; median move was -0.4%, versus +0.8% for the S&P 500
Clinical evidence and integration agreements drove the top gains, led by ISRG and SENS
Litigation overhang hit hardest at the procedure-led end: PRCT fell -17.9%
One agreed deal (Haemonetics) left the 40-deal precedent set unchanged at 8.3x

What each page shows

The analyst’s walkthrough of the deck, page by page.

01
BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE
HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › MEDICAL DEVICES
Cover page introducing the Medical Devices bi-weekly industry events and M&A update for September 14–28, 2026.
This bi-weekly update covers Medical Devices for September 14–28, 2026 — what changed, who moved and why, what transacted, and what it means. We'll walk through the period's public market movers, major catalysts, the one agreed transaction, and the implications for operators, buyers and advisers.
Everything on this page
BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › MEDICAL DEVICES Evidence and Integration Earn the Bid; Legal Overhang Takes It Back This update covers Medical Devices over September 14–28, 2026: the period's movers, company news and the one transaction the parties agreed during the window. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Medical Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1
02
THE BI-WEEKLY BOTTOM LINE
Clinical Evidence and Recurring-Revenue Partnerships Set the Winners
Summarizes the two-week period's market performance and the four themes that set the winners and losers among 30 covered names.
Over the two weeks, 17 of the 30 covered names fell, with the median move at -0.4% against a +0.8% gain for the S&P 500, so the group lagged the broader market. The upside was concentrated in clinical evidence and recurring-revenue partnerships: Intuitive Surgical (ISRG) gained +9.8% after a da Vinci meta-analysis, and Senseonics (SENS) rose +11.3% on its Eversense 365 integration agreement. The sharpest declines sat with litigation overhang, most visibly at PROCEPT BioRobotics (PRCT), down -17.9%. One agreed transaction — Haemonetics (HAE) — kept the trailing 40-deal precedent record at a median 8.3x EV/LTM EBITDA, so the standing valuation frame held through the period.
Everything on this page
THE BI-WEEKLY BOTTOM LINE Clinical Evidence and Recurring-Revenue Partnerships Set the Winners The two-week period in one page · 30 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Medical Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 17 of 30 Covered Names Fell; The Median Move Was -0.4% The median covered name slipped -0.4% while the S&P 500 returned +0.8%, so the group lagged the broad market over the two-week period. The spread inside the set was wide, from RxSight, Inc. (RXST) at -23.6% to Avita Medical Inc. (RCEL) at +14.5%. 2 Clinical Data and an Integration Deal Carried the Upside Intuitive Surgical, Inc. (ISRG) gained +9.8% over the period following a da Vinci meta-analysis reported on Sep 15. Senseonics Holdings, Inc. (SENS) rose +11.3% after announcing an agreement to integrate Eversense 365 with an automated insulin delivery system. 3 Litigation Overhang Priced Hardest at the Procedure-Led End PROCEPT BioRobotics Corporation (PRCT) fell -17.9%, including -8.2% on Sep 15, with securities class action notices dated Sep 14 the visible in-window record. The complaint described in those notices centres on how consumable demand was recognised. 4 One Agreed Transaction; The Standing Valuation Frame Holds Haemonetics Corporation (HAE) was named in the period's one agreed transaction, and no completed precedent transactions were added to the record. The trailing record of 40 transactions carries a median EV/EBITDA of 8.3x, and the standing sector median of 3.4x forward revenue frames the split the period's moves followed. +14.5% Best mover — Avita Medical Inc. (RCEL) worst: RXST -23.6% · 13 up / 17 down of 30 covered -0.4% Sector median two-week return vs S&P 500 +0.8% 1 Transaction agreed in the two-week period from company announcements; not yet in the precedent record 1 Company filings in the window 8-K events read for driver attribution
03
PUBLIC MARKET MOVERS
Evidence and Integration Deals Earned the Bid; Legal Overhang Took the Toll
Ranks the period's public market movers against the sector median, the S&P 500 and a ±5.8% materiality bar.
Close-to-close over September 14–28, 2026, the sector median move was -0.4% while the S&P 500 returned +0.8%, so the covered group trailed the broad market. Against a ±5.8% materiality bar, the widest swings ran from RxSight (RXST) at -23.6% to Avita Medical (RCEL) at +14.5%, marking the range investors actually priced. We link each flagged move only to the filings and headlines recorded in the window, and where no driver is recorded, we say so plainly. That discipline is what lets us separate evidence-and-integration winners from names still carrying legal overhang.
Everything on this page
PUBLIC MARKET MOVERS Evidence and Integration Deals Earned the Bid; Legal Overhang Took the Toll Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median -0.4% · S&P 500 +0.8% · materiality bar ±5.8% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Medical Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median -0.4% PROCEPT BioRobotics Corporation (PRCT) -17.9% Shares fell -17.9%, including -8.2% on Sep 15, following the Sep 14 securities class action notices. Litigation over how consumable demand was booked strikes at the razor-and-blade case itself. COMPANY-SPECIFIC Avita Medical Inc. (RCEL) +14.5% Shares rose +14.5%, with a +7.4% session on Sep 17, following the company's Sep 16 presentation at the Morgan Stanley 24th Annual Global Healthcare Conference. The available evidence suggests that update was the most visible in-window item. Core-tier ramp stories still reprice on what management says in public about adoption. COMPANY-SPECIFIC Embecta Corp. (EMBC) +13.2% No notable in-window news was identified that clearly explains the move. The +13.2% return sat well above the -0.4% median for covered names. Discount-tier names move sharply on modest flow; the rerating case still runs through recurring mix. UNEXPLAINED Senseonics Holdings, Inc. (SENS) +11.3% Shares moved following the Sep 14 announcement of a partnership to integrate Eversense 365 with an automated insulin delivery system; the partner confirmed the agreement on Sep 22. The best session was +4.1% on Sep 17. Integration agreements widen an installed base without paying to build a new channel. COMPANY-SPECIFIC
04
MAJOR NEWS & INDUSTRY CATALYSTS
What Companies Actually Did: Automation, Integration, Evidence and a Portfolio Separation
Walks through the two-week period's highest-impact company actions — automation, integration, clinical evidence and a portfolio separation.
This page walks through the period's highest-impact company actions, each linked to its underlying filing or article. Intuitive Surgical's da Vinci meta-analysis and Senseonics' Eversense 365 integration agreement stand out as the evidence- and partnership-led catalysts the market rewarded. Other names moved on automation initiatives and a portfolio separation recorded during the window, underscoring how varied the two weeks' catalysts were. Reading these events together helps clients separate durable strategic moves from short-term news flow.
Everything on this page
MAJOR NEWS & INDUSTRY CATALYSTS What Companies Actually Did: Automation, Integration, Evidence and a Portfolio Separation The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Medical Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 15 · NEWS · Business Wire Cognyte won a new contract with a long-standing national security customer in Asia-Pacific A repeat order from an existing customer is a direct read on retention and account depth. For a Discount-tier name, renewals are the evidence that revenue quality is improving. Order flow from installed customers is the cleanest revenue-quality signal in adjacent models. Sep 14 · NEWS · PRNewsWire BD deployed its Vmax 160 pharmacy robotics in a first-of-its-kind US health system installation Placing automation inside a health system extends the hospital call point beyond dispensing. Capital placements of this kind are what lock in downstream pull-through. Enabling hardware earns its multiple through what it locks in, not through systems revenue. Sep 14 · NEWS · GlobeNewsWire Senseonics agreed to integrate Eversense 365 with an automated insulin delivery system The agreement puts a year-long sensor in front of an existing pump user base. That deepens recurring revenue rather than adding another standalone device to sell. Deals that widen the installed base are worth more than launches to a Core-tier name. Sep 14 · NEWS · PRNewsWire Medtronic launched a share exchange offer to complete a planned separation of one of its groups Diversified strategics are as active pruning portfolios as they are buying. A completed separation frees capital and management attention for the franchises the company keeps. Separations keep feeding the buyer universe with mature, cash-generative product lines. Sep 15 · 8-K · SEC EDGAR Pulse Biosciences completed enrollment in its PRECISE-BTN study and reached first 12-month follow-up Evidence milestones, not product launches, are what this sector reprices around. Completed enrollment puts a clock on the data read that supports coverage, coding and payment. Pivotal data timing is the calendar item buyers and boards plan against. Sep 14 · NEWS · GlobeNewsWire PROCEPT BioRobotics faced a securities class action with a lead-plaintiff deadline inside the period The complaint centres on how consumable demand was recognised, which puts the durability of razor-and-blade economics under scrutiny across the procedure-led group. Litigation overhang is priced as a standing value detractor, not a one-off legal cost.
05
M&A & STRATEGIC ACTIVITY
Haemonetics' Agreed Acquisition Triggers a Milestone Payout — the Period's One Transaction
Details Haemonetics' agreed acquisition, the period's only transaction, against the trailing precedent set of 40 deals at a median 8.3x EV/LTM EBITDA.
Haemonetics (HAE) was named in the period's one agreed transaction, triggering a milestone payout under the deal terms. No completed transactions were added to the precedent record during the window, so the trailing set of 40 deals still carries a median 8.3x EV/LTM EBITDA. That stability gives buyers and sellers a steady reference point even as public trading moved sharply on either side. For advisers, it signals that deal pricing discipline in the space has not shifted despite the volatility in public names.
Everything on this page
M&A & STRATEGIC ACTIVITY Haemonetics' Agreed Acquisition Triggers a Milestone Payout — the Period's One Transaction September 14–28, 2026 · 1 agreed by company announcement · precedent transactions: 40 recorded deals · median 8.3x EV/LTM EBITDA Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Medical Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 AGREED IN THE PERIOD — FROM COMPANY ANNOUNCEMENTS Sep 15 · Haemonetics Corporation (HAE) Haemonetics Corporation (HAE) acquires a device business, triggering a milestone payment to a partner in the asset The structure is the sector's standard: value paid in stages rather than in one upfront. It suggests strategics still buy early-commercial technology with the upfront calibrated to the evidence already in hand. Terms and multiples enter the precedent record once the filing is processed; the reference set alongside is unchanged. 40 Recorded precedent transactions the reference set buyers and sellers price against 8.3x Precedent median EV/LTM EBITDA LTM at announcement, where disclosed
06
WHAT IT MEANS
What the Period Changes for Operators, Buyers and Advisers
Translates the period's evidence into implications for operators, acquirers and advisers.
For owners and operators, the period rewarded recurring-revenue mix and attach rate: companies with new clinical evidence or a signed integration agreement traded higher. For acquirers, the reference set held steady — one agreed transaction and an unchanged trailing median of 8.3x EV/LTM EBITDA across 40 deals — so pricing discipline persisted through the window. For advisers, the strongest moves followed a clinical meta-analysis and an integration deal, while the sharpest declines sat with litigation over consumable-demand recognition, reinforcing the case for leading with evidence over product story. Together, these reads point clients toward the same lesson: evidence and recurring economics, not headlines, are what the market is pricing.
Everything on this page
WHAT IT MEANS What the Period Changes for Operators, Buyers and Advisers The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Medical Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 EV / Revenue (CY2027E) median 3.4x 33 companies in the study 3 valuation tiers Standing thesis: Medical Devices Split Between Diversified Platforms, Procedure-Led Franchises and Lower-Valued Adjacent Models FOR OWNERS & OPERATORS Recurring Mix and Attach Rate Were the Levers the Period Rewarded Companies in the space that showed new clinical evidence or a signed integration agreement traded higher over the two-week period. FOR ACQUIRERS One Agreed Transaction, Staged Consideration, and an Unchanged Reference Set No completed transactions were added to the record over the period; the trailing record of 40 transactions still carries a median EV/EBITDA of 8.3x. FOR ADVISORS Lead with Evidence and Attach Economics, Not with the Product Story The strongest moves followed a clinical meta-analysis and an integration agreement; the sharpest declines sat with a name carrying litigation over how consumable demand was booked.
07
SOURCES & METHODOLOGY
Sources, Methodology and Important Notice
Explains the sources and methodology behind every figure and driver attribution in the update.
Every figure in this update links back to the SEC filing, press release or market price it was taken from, so clients can verify each number at the source. Driver attributions use calibrated language — they are our reads of the recorded evidence, not asserted causation. Sources are admitted in a fixed reliability order, with video and social platforms excluded entirely. This discipline is what lets clients trust the update's calls without needing to re-derive them.
Everything on this page
SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Medical Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. 3 names below the floor were excluded from movers and statistics for this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T151912Z_518_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: businesswire.com · prnewswire.com · globenewswire.com · sec.gov

Sources and methodology

This update covers Medical Devices over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 30 listed companies whose core business is Medical Devices under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Anika Therapeutics, Inc. (ANIK), Alphatec Holdings, Inc. (ATEC), AxoGen, Inc. (AXGN), Azenta, Inc. (AZTA), Becton, Dickinson and Company (BDX), Boston Scientific Corporation (BSX), Cerus Corporation (CERS), Cognyte Software Ltd. (CGNT), Delcath Systems, Inc. (DCTH), Alpha Tau Medical Ltd (DRTS), Embecta Corp. (EMBC), Glaukos Corporation (GKOS), Globus Medical, Inc. (GMED), Haemonetics Corporation (HAE), Integra LifeSciences Holdings Corporation (IART), Inogen, Inc. (INGN), InMode Ltd. (INMD), Intuitive Surgical, Inc. (ISRG), Medtronic plc (MDT), Penumbra, Inc. (PEN), Pulse Biosciences, Inc. (PLSE), PROCEPT BioRobotics Corporation (PRCT), Profound Medical Corp. (PROF), Avita Medical Inc. (RCEL), ResMed Inc. (RMD), RxSight, Inc. (RXST), Senseonics Holdings, Inc. (SENS), Stevanato Group S.p.A. (STVN), TransMedics Group, Inc. (TMDX), West Pharmaceutical Services, Inc. (WST). 3 names below the floor were excluded from the statistics: LUNG, NYXH, SRTS.

Window and company universe

How the moves and statistics are computed

Each company's period move is the change in closing price from the last close before the window to the last close inside it (close-to-close). The sector median is the median of those moves across the covered names; the index return is computed the same way for the S&P 500 over the same dates. The largest single-day move inside the window is shown for each mover. Movers are the largest gainers and losers by period move; the attribution cards prefer movers whose in-window record explains the move. Movers carry the valuation tier assigned in the standing sector study (the latest NeuraCap sector outlook) where that study rated them.

Events, news and how a move is attributed

Company events are the 8-K filings made inside the window; news items are publisher-sourced headlines for the window, admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron's and peers). Video and social platforms are never used. A move is linked to an event only when the event falls inside the window and only in calibrated language; where nothing in the record explains a move, the update says so rather than speculating. Every event links to its source.

Transactions in the window and the trailing record

Transactions are taken from SEC filings by announcement date; 0 were announced inside the window. The trailing record of 40 recorded transactions provides the reference multiples (EV over last-twelve-month revenue or EBITDA at announcement, as disclosed). A value whose own citation describes something other than the price paid is not shown as the deal value; transactions where the acquirer and the target are the same entity are treated as reorganisations and excluded.

Sources

Prices and index levels are market data through September 28, 2026; filings are the companies' SEC filings on EDGAR; press releases are the companies' own; other news items are from the established outlets named on each card; Treasury yields are published by the U.S. Department of the Treasury. Every figure and every event in the update links to its record.

Interpretation and important notice

'Why it matters', 'why the deal happened' and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, labelled as such. The update is informational: it is not investment advice, not a recommendation to buy or sell any security and not an offer of any kind.

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

More coverage in Health Care

Want this analysis for a company in Medical Devices?

Company valuation reports run the same method against a single business — public or private.

Get your report Talk to advisory

Medical Devices Bi-Weekly Industry Events & M&A Update — September 14–28, 2026

Key figures

Read the report

Executive summary

Key findings

What each page shows

HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › MEDICAL DEVICES

Clinical Evidence and Recurring-Revenue Partnerships Set the Winners

Evidence and Integration Deals Earned the Bid; Legal Overhang Took the Toll

What Companies Actually Did: Automation, Integration, Evidence and a Portfolio Separation

Haemonetics' Agreed Acquisition Triggers a Milestone Payout — the Period's One Transaction

What the Period Changes for Operators, Buyers and Advisers

Sources, Methodology and Important Notice